UB 421

Drug Profile

UB 421

Alternative Names: dB4; dB4C7 mAb; mAb B4; UB421

Latest Information Update: 24 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator United Biomedical
  • Developer United Biomedical; United BioPharma
  • Class Antiretrovirals; Monoclonal antibodies
  • Mechanism of Action HIV fusion inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 25 May 2017 United BioPharma plans a phase II/III trial for HIV-1 infection (Adjunctive therapy) (NCT03164447)
  • 13 Feb 2017 Safety and efficacy data from a phase IIIb trial in HIV-1 infections presented at the 24th Conference on Retroviruses and Opportunistic Infections (CROI-2017)
  • 28 Nov 2016 United Biomedical plans a phase III trial for HIV-1 infections (Monotherapy) (NCT03149211)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top